<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39364337</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2468-0427</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Infectious Disease Modelling</Title><ISOAbbreviation>Infect Dis Model</ISOAbbreviation></Journal><ArticleTitle>A data science pipeline applied to Australia's 2022 COVID-19 Omicron waves.</ArticleTitle><Pagination><StartPage>99</StartPage><EndPage>109</EndPage><MedlinePgn>99-109</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.idm.2024.08.005</ELocationID><Abstract><AbstractText>The field of software engineering is advancing at astonishing speed, with packages now available to support many stages of data science pipelines. These packages can support infectious disease modelling to be more robust, efficient and transparent, which has been particularly important during the COVID-19 pandemic. We developed a package for the construction of infectious disease models, integrated it with several open-source libraries and applied this composite pipeline to multiple data sources that provided insights into Australia's 2022 COVID-19 epidemic. We aimed to identify the key processes relevant to COVID-19 transmission dynamics and thereby develop a model that could quantify relevant epidemiological parameters. The pipeline's advantages include markedly increased speed, an expressive application programming interface, the transparency of open-source development, easy access to a broad range of calibration and optimisation tools and consideration of the full workflow from input manipulation through to algorithmic generation of the publication materials. Extending the base model to include mobility effects slightly improved model fit to data, with this approach selected as the model configuration for further epidemiological inference. Under our assumption of widespread immunity against severe outcomes from recent vaccination, incorporating an additional effect of the main vaccination programs rolled out during 2022 on transmission did not further improve model fit. Our simulations suggested that one in every two to six COVID-19 episodes were detected, subsequently emerging Omicron subvariants escaped 30-60% of recently acquired natural immunity and that natural immunity lasted only one to eight months on average. We documented our analyses algorithmically and present our methods in conjunction with interactive online code notebooks and plots. We demonstrate the feasibility of integrating a flexible domain-specific syntax library with state-of-the-art packages in high performance computing, calibration, optimisation and visualisation to create an end-to-end pipeline for infectious disease modelling. We used the resulting platform to demonstrate key epidemiological characteristics of the transition from the emergency to the endemic phase of the COVID-19 pandemic.</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Trauer</LastName><ForeName>James M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hughes</LastName><ForeName>Angus E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shipman</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meehan</LastName><ForeName>Michael T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henderson</LastName><ForeName>Alec S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McBryde</LastName><ForeName>Emma S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ragonnet</LastName><ForeName>Romain</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Infect Dis Model</MedlineTA><NlmUniqueID>101692406</NlmUniqueID><ISSNLinking>2468-0427</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Computational simulation</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Software design</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>8</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>8</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>4</Day><Hour>4</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39364337</ArticleId><ArticleId IdType="pmc">PMC11447346</ArticleId><ArticleId IdType="doi">10.1016/j.idm.2024.08.005</ArticleId><ArticleId IdType="pii">S2468-0427(24)00098-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Altarawneh H.N., Chemaitelly H., Ayoub H.H., Hasan M.R., Coyle P., Yassine H.M., Al-Khatib H.A., Smatti M.K., Al-Kanaani Z., Al-Kuwari E., Jeremijenko A., Kaleeckal A.H., Latif A.N., Shaik R.M., Abdul-Rahim H.F., Nasrallah G.K., Al-Kuwari M.G., Butt A.A., Al-Romaihi H.E.…Abu-Raddad L.J. Protective effect of previous SARS-CoV-2 infection against omicron BA.4 and BA.5 subvariants. New England Journal of Medicine. 2022;387(17):1620–1622. doi: 10.1056/NEJMc2209306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2209306</ArticleId><ArticleId IdType="pmc">PMC9559315</ArticleId><ArticleId IdType="pubmed">36198139</ArticleId></ArticleIdList></Reference><Reference><Citation>Braeye T., Catteau L., Brondeel R., van Loenhout J.A.F., Proesmans K., Cornelissen L., Van Oyen H., Stouten V., Hubin P., Billuart M., Djiena A., Mahieu R., Hammami N., Van Cauteren D., Wyndham-Thomas C. Vaccine effectiveness against transmission of alpha, delta and omicron SARS-COV-2-infection, Belgian contact tracing, 2021-2022. Vaccine. 2023;41(20):3292–3300. doi: 10.1016/j.vaccine.2023.03.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2023.03.069</ArticleId><ArticleId IdType="pmc">PMC10073587</ArticleId><ArticleId IdType="pubmed">37085456</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgdorf K.S., Simonsen J., Sundby A., Rostgaard K., Pedersen O.B., Sørensen E., Nielsen K.R., Bruun M.T., Frisch M., Edgren G., Erikstrup C., Hjalgrim H., Ullum H. Socio-demographic characteristics of Danish blood donors. PLoS One. 2017;12(2) doi: 10.1371/journal.pone.0169112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0169112</ArticleId><ArticleId IdType="pmc">PMC5300150</ArticleId><ArticleId IdType="pubmed">28182624</ArticleId></ArticleIdList></Reference><Reference><Citation>Caldwell J.M., de Lara-Tuprio E., Teng T.R., Estuar M.R.J.E., Sarmiento R.F.R., Abayawardana M., Leong R.N.F., Gray R.T., Wood J.G., Le L.-V., McBryde E.S., Ragonnet R., Trauer J.M. Understanding COVID-19 dynamics and the effects of interventions in the Philippines: A mathematical modelling study. The Lancet Regional Health – Western Pacific. 2021;14 doi: 10.1016/j.lanwpc.2021.100211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2021.100211</ArticleId><ArticleId IdType="pmc">PMC8279002</ArticleId><ArticleId IdType="pubmed">34308400</ArticleId></ArticleIdList></Reference><Reference><Citation>Carazo S., Skowronski D.M., Brisson M., Barkati S., Sauvageau C., Brousseau N., Gilca R., Fafard J., Talbot D., Ouakki M., Gilca V., Carignan A., Deceuninck G., De Wals P., De Serres G. Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: A test-negative case-control study. The Lancet Infectious Diseases. 2023;23(1):45–55. doi: 10.1016/S1473-3099(22)00578-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00578-3</ArticleId><ArticleId IdType="pmc">PMC9491856</ArticleId><ArticleId IdType="pubmed">36152671</ArticleId></ArticleIdList></Reference><Reference><Citation>Chemaitelly H., Ayoub H.H., Coyle P., Tang P., Yassine H.M., Al-Khatib H.A., Smatti M.K., Hasan M.R., Al-Kanaani Z., Al-Kuwari E., Jeremijenko A., Kaleeckal A.H., Latif A.N., Shaik R.M., Abdul-Rahim H.F., Nasrallah G.K., Al-Kuwari M.G., Butt A.A., Al-Romaihi H.E.…Abu-Raddad L.J. Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage. Nature Communications. 2022;13(1):4675. doi: 10.1038/s41467-022-32363-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-32363-4</ArticleId><ArticleId IdType="pmc">PMC9362989</ArticleId><ArticleId IdType="pubmed">35945213</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Nadeau S., Yared M., Voinov P., Xie N., Roemer C., Stadler T. CoV-spectrum: Analysis of globally shared SARS-CoV-2 data to identify and characterize new variants. Bioinformatics. 2022;38(6):1735–1737. doi: 10.1093/bioinformatics/btab856.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btab856</ArticleId><ArticleId IdType="pmc">PMC8896605</ArticleId><ArticleId IdType="pubmed">34954792</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 National Incident Room, Surveillance Team COVID-19 Australia: Epidemiology report 58. Reporting period ending 13 Febraury 2022. Communicable Diseases Intelligence. 2022;46 doi: 10.33321/cdi.2022.46.9. 24/3/2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.33321/cdi.2022.46.9</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 National Incident Room, Surveilance Team . 2023. COVID-19 Australia: Epidemiology Report 69. Reporting period ending 18 December 2022. (Coronavirus disease 2019 (COVID-19) epidemiology reports; pp. 2022–2023. Australia. Issue.</Citation></Reference><Reference><Citation>Dunstan J.  ABC News; 2022. There's no Victorian COVID-19 lockdown, but Melburnians are choosing to stay home anyway.https://www.abc.net.au/news/2022-01-19/victoria-melbourne-covid-shadow-lockdown-cbd-mobility/100753496?utm_campaign=abc_news_web&amp;utm_content=link&amp;utm_medium=content_shared&amp;utm_source=abc_news_web</Citation></Reference><Reference><Citation>Edridge A.W.D., Kaczorowska J., Hoste A.C.R., Bakker M., Klein M., Loens K., Jebbink M.F., Matser A., Kinsella C.M., Rueda P., Ieven M., Goossens H., Prins M., Sastre P., Deijs M., van der Hoek L. Seasonal coronavirus protective immunity is short-lasting. Nature Medicine. 2020;26(11):1691–1693. doi: 10.1038/s41591-020-1083-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1083-1</ArticleId><ArticleId IdType="pubmed">32929268</ArticleId></ArticleIdList></Reference><Reference><Citation>Erikstrup C., Laksafoss A.D., Gladov J., Kaspersen K.A., Mikkelsen S., Hindhede L., Boldsen J.K., Jørgensen S.W., Ethelberg S., Holm D.K., Bruun M.T., Nissen J., Schwinn M., Brodersen T., Mikkelsen C., Sækmose S.G., Sørensen E., Harritshøj L.H., Aagaard B.…Pedersen O.B.V. Seroprevalence and infection fatality rate of the SARS-CoV-2 omicron variant in Denmark: A nationwide serosurveillance study. The Lancet Regional Health – Europe. 2022;21 doi: 10.1016/j.lanepe.2022.100479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2022.100479</ArticleId><ArticleId IdType="pmc">PMC9355516</ArticleId><ArticleId IdType="pubmed">35959415</ArticleId></ArticleIdList></Reference><Reference><Citation>Gidding H.F., Machalek D.A., Hendry A.J., Quinn H.E., Vette K., Beard F.H., Shilling H.S., Hirani R., Gosbell I.B., Irving D.O., Hueston L., Downes M., Carlin J.B., O'Sullivan M.V.N., Dwyer D.E., Kaldor J.M., Macartney K. Seroprevalence of SARS-CoV-2-specific antibodies in Sydney after the first epidemic wave of 2020. Medical Journal of Australia. 2021;214(4):179–185. doi: 10.5694/mja2.50940.</Citation><ArticleIdList><ArticleId IdType="doi">10.5694/mja2.50940</ArticleId><ArticleId IdType="pmc">PMC8014239</ArticleId><ArticleId IdType="pubmed">33538019</ArticleId></ArticleIdList></Reference><Reference><Citation>Google LLC. Google COVID-19 Community Mobility Reports. Retrieved 30/11/2023 from https://www.google.com/covid19/mobility/.</Citation></Reference><Reference><Citation>Grefenstette J.J., Brown S.T., Rosenfeld R., DePasse J., Stone N.T.B., Cooley P.C., Wheaton W.D., Fyshe A., Galloway D.D., Sriram A., Guclu H., Abraham T., Burke D.S. FRED (A framework for reconstructing epidemic dynamics): An open-source software system for modeling infectious diseases and control strategies using census-based populations. BMC Public Health. 2013;13(1):940. doi: 10.1186/1471-2458-13-940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2458-13-940</ArticleId><ArticleId IdType="pmc">PMC3852955</ArticleId><ArticleId IdType="pubmed">24103508</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen C.H., Friis N.U., Bager P., Stegger M., Fonager J., Fomsgaard A., Gram M.A., Christiansen L.E., Ethelberg S., Legarth R., Krause T.G., Ullum H., Valentiner-Branth P. Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: A nation-wide population-based study in Denmark. The Lancet Infectious Diseases. 2023;23(2):167–176. doi: 10.1016/S1473-3099(22)00595-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00595-3</ArticleId><ArticleId IdType="pmc">PMC9578720</ArticleId><ArticleId IdType="pubmed">36270311</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinch R., Probert W.J.M., Nurtay A., Kendall M., Wymant C., Hall M., Lythgoe K., Bulas Cruz A., Zhao L., Stewart A., Ferretti L., Montero D., Warren J., Mather N., Abueg M., Wu N., Legat O., Bentley K., Mead T.…Fraser C. OpenABM-Covid19—an agent-based model for non-pharmaceutical interventions against COVID-19 including contact tracing. PLoS Computational Biology. 2021;17(7) doi: 10.1371/journal.pcbi.1009146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1009146</ArticleId><ArticleId IdType="pmc">PMC8328312</ArticleId><ArticleId IdType="pubmed">34252083</ArticleId></ArticleIdList></Reference><Reference><Citation>Horner J.K., Symons J.F. Software engineering standards for epidemiological models. History &amp; Philosophy of the Life Sciences. 2020;42(4):54. doi: 10.1007/s40656-020-00347-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40656-020-00347-6</ArticleId><ArticleId IdType="pmc">PMC7653982</ArticleId><ArticleId IdType="pubmed">33170375</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes A., Ragonnet R., Jayasundara P., Ngo H.-A., de Lara-Tuprio E., Estuar M.R.J., Teng T.R., Boon L.K., Peariasamy K.M., Chong Z.-L., Ghazali I.M.M., Fox G.J., Nguyen T.-A., Le L.-V., Abayawardana M., Shipman D., McBryde E.S., Meehan M.T., Caldwell J.M., Trauer J.M. COVID-19 collaborative modelling for policy response in the Philippines, Malaysia and Vietnam. The Lancet Regional Health – Western Pacific. 2022;29 doi: 10.1016/j.lanwpc.2022.100563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanwpc.2022.100563</ArticleId><ArticleId IdType="pmc">PMC9371475</ArticleId><ArticleId IdType="pubmed">35974800</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayasundara P., Peariasamy K.M., Law K.B., Abd Rahim K.N.K., Lee S.W., Ghazali I.M.M., Abayawardana M., Le L.V., Khalaf R.K.S., Razali K., Le X., Chong Z.L., McBryde E.S., Meehan M.T., Caldwell J.M., Ragonnet R., Trauer J.M. Sustaining effective COVID-19 control in Malaysia through large-scale vaccination. Epidemics. 2021;37 doi: 10.1016/j.epidem.2021.100517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.epidem.2021.100517</ArticleId><ArticleId IdType="pmc">PMC8547797</ArticleId><ArticleId IdType="pubmed">34739906</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr C.C., Stuart R.M., Mistry D., Abeysuriya R.G., Rosenfeld K., Hart G.R., Núñez R.C., Cohen J.A., Selvaraj P., Hagedorn B., George L., Jastrzębski M., Izzo A.S., Fowler G., Palmer A., Delport D., Scott N., Kelly S.L., Bennette C.S.…Klein D.J. Covasim: An agent-based model of COVID-19 dynamics and interventions. PLoS Computational Biology. 2021;17(7) doi: 10.1371/journal.pcbi.1009149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1009149</ArticleId><ArticleId IdType="pmc">PMC8341708</ArticleId><ArticleId IdType="pubmed">34310589</ArticleId></ArticleIdList></Reference><Reference><Citation>Kissler S.M., Tedijanto C., Goldstein E., Grad Y.H., Lipsitch M. 05). Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science. 2020;368(6493):860–868. doi: 10.1126/science.abb5793.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb5793</ArticleId><ArticleId IdType="pmc">PMC7164482</ArticleId><ArticleId IdType="pubmed">32291278</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar R., Carroll C., Hartikainen A., Martin O. ArviZ a unified library for exploratory analysis of Bayesian models in Python. Journal of Open Source Software. 2019;4(33):1143. doi: 10.21105/joss.01143.</Citation><ArticleIdList><ArticleId IdType="doi">10.21105/joss.01143</ArticleId></ArticleIdList></Reference><Reference><Citation>Lloyd M.  ABC News; 2022. Omicron COVID-19 spread hits Australian small business, creating 'shadow lockdown' and soft trading conditions.https://www.abc.net.au/news/2022-01-23/omicron-covid-spread-hits-australian-small-business/100772382?utm_campaign=abc_news_web&amp;utm_content=link&amp;utm_medium=content_shared&amp;utm_source=abc_news_web Retrieved 1/12/2023, from.</Citation></Reference><Reference><Citation>Machalek D., Aung E., Kaldor J., Winkler N., Gidding H., Maccartney K., Hirani R., Diaz P., Gosbell I., Irving D., Nicholson S., Karapanagiotidis T., Brizuela R., Cain N., Huang H., Hernandez K., Williamson D., O'Sullivan M., Carlin J., Downes M., Balgovind P. Seroprevalence of SARS-CoV-2-specific antibodies among Australian blood donors: Round 4 update (4) 2023. https://www.kirby.unsw.edu.au/research/projects/serosurveillance-sars-cov-2-infection-inform-public-health-responses (Serosurveillance for SARS-CoV-2 infection to inform public health response, Issue.</Citation></Reference><Reference><Citation>Machalek D.A., Vette K.M., Downes M., Carlin J.B., Nicholson S., Hirani R., Irving D.O., Gosbell I.B., Gidding H.F., Shilling H., Aung E., Macartney K., Kaldor J.M. Serological testing of blood donors to characterise the impact of COVID-19 in Melbourne, Australia, 2020. PLoS One. 2022;17(7) doi: 10.1371/journal.pone.0265858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0265858</ArticleId><ArticleId IdType="pmc">PMC9258843</ArticleId><ArticleId IdType="pubmed">35793307</ArticleId></ArticleIdList></Reference><Reference><Citation>Malato J., Ribeiro R.M., Leite P.P., Casaca P., Fernandes E., Antunes C., Fonseca V.R., Gomes M.C., Graca L. Risk of BA.5 infection among persons exposed to previous SARS-CoV-2 variants. New England Journal of Medicine. 2022;387(10):953–954. doi: 10.1056/NEJMc2209479.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2209479</ArticleId><ArticleId IdType="pmc">PMC9454644</ArticleId><ArticleId IdType="pubmed">36044619</ArticleId></ArticleIdList></Reference><Reference><Citation>McCaw J.M., Plank M.J. The role of the mathematical sciences in supporting the COVID-19 response in Australian and New Zealand. ANZIAM Journal. 2022;64(4):315–337. doi: 10.1017/S1446181123000123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1446181123000123</ArticleId></ArticleIdList></Reference><Reference><Citation>Mossong J., Hens N., Jit M., Beutels P., Auranen K., Mikolajczyk R., Massari M., Salmaso S., Tomba G.S., Wallinga J., Heijne J., Sadkowska-Todys M., Rosinska M., Edmunds W.J. Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Medicine. 2008;5(3) doi: 10.1371/journal.pmed.0050074.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.0050074</ArticleId><ArticleId IdType="pmc">PMC2270306</ArticleId><ArticleId IdType="pubmed">18366252</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Driscoll M., Ribeiro Dos Santos G., Wang L., Cummings D.A.T., Azman A.S., Paireau J., Fontanet A., Cauchemez S., Salje H. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2021;590(7844):140–145. doi: 10.1038/s41586-020-2918-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2918-0</ArticleId><ArticleId IdType="pubmed">33137809</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagel C., Yates C.A. Role of mathematical modelling in future pandemic response policy. BMJ. 2022;378 doi: 10.1136/bmj-2022-070615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-070615</ArticleId><ArticleId IdType="pubmed">36109042</ArticleId></ArticleIdList></Reference><Reference><Citation>Plotly Technologies Inc.  Collaborative data science (Version 5.23) [Computer software]. Plotly technologies inc. 2015. https://plot.ly</Citation></Reference><Reference><Citation>Powell A.A., Kirsebom F., Stowe J., Ramsay M.E., Lopez-Bernal J., Andrews N., Ladhani S.N. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021 - March, 2022: A national, observational, test-negative, case-control study. The Lancet Infectious Diseases. 2023;23(4):435–444. doi: 10.1016/S1473-3099(22)00729-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00729-0</ArticleId><ArticleId IdType="pmc">PMC10032664</ArticleId><ArticleId IdType="pubmed">36436536</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapin J., Teytaud O. Nevergrad - A gradient-free optimization platform (Version 1.04) [Computer software] 2018. https://GitHub.com/FacebookResearch/Nevergrad GitHub.</Citation></Reference><Reference><Citation>Robertson C., Kerr S., Sheikh A. Severity of omicron BA.5 variant and protective effect of vaccination: National cohort and matched analyses in scotland. The Lancet Regional Health – Europe. 2023;28 doi: 10.1016/j.lanepe.2023.100638.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2023.100638</ArticleId><ArticleId IdType="pmc">PMC10139952</ArticleId><ArticleId IdType="pubmed">37124948</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvatier J., Wiecki T.V., Fonnesbeck C. Probabilistic programming in Python using PyMC3. PeerJ Computer Science. 2016;2:e55. doi: 10.7717/peerj-cs.55.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj-cs.55</ArticleId><ArticleId IdType="pmc">PMC10495961</ArticleId><ArticleId IdType="pubmed">37705656</ArticleId></ArticleIdList></Reference><Reference><Citation>Shipman D., Ragonnet R., Trauer J.M. Estival. In. 2024. https://github.com/monash-emu/estival</Citation></Reference><Reference><Citation>Shipman D., Trauer J.M., Ragonnet R., Segal M. Summerepi2. In. 2024. https://github.com/monash-emu/summer2</Citation></Reference><Reference><Citation>Tan C.Y., Chiew C.J., Pang D., Lee V.J., Ong B., Lye D.C., Tan K.B. Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study. The Lancet Infectious Diseases. 2023;23(7):799–805. doi: 10.1016/S1473-3099(23)00060-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00060-9</ArticleId><ArticleId IdType="pmc">PMC10306341</ArticleId><ArticleId IdType="pubmed">36924786</ArticleId></ArticleIdList></Reference><Reference><Citation>Timms P., Lloyd M.  ABC News; 2022. COVID-19 testing under pressure across Australia, as rapid antigen tests remain hard to find amid long delays for PCRs [report]https://www.abc.net.au/news/2022-01-05/covid-testing-pcr-delays-rat-test-supply-issues/100738982?utm_campaign=abc_news_web&amp;utm_content=link&amp;utm_medium=content_shared&amp;utm_source=abc_news_web Retrieved 1/12/2023, from.</Citation></Reference><Reference><Citation>Townsend J.P., Hassler H.B., Wang Z., Miura S., Singh J., Kumar S., Ruddle N.H., Galvani A.P., Dornburg A. The durability of immunity against reinfection by SARS-CoV-2: A comparative evolutionary study. The Lancet Microbe. 2021;2(12):e666–e675. doi: 10.1016/S2666-5247(21)00219-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00219-6</ArticleId><ArticleId IdType="pmc">PMC8486316</ArticleId><ArticleId IdType="pubmed">34632431</ArticleId></ArticleIdList></Reference><Reference><Citation>Trauer J.M., Lydeamore M.J., Dalton G.W., Pilcher D., Meehan M.T., McBryde E.S., Cheng A.C., Sutton B., Ragonnet R. Understanding how Victoria, Australia gained control of its second COVID-19 wave. Nature Communications. 2021;12(1):6266. doi: 10.1038/s41467-021-26558-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-26558-4</ArticleId><ArticleId IdType="pmc">PMC8560916</ArticleId><ArticleId IdType="pubmed">34725323</ArticleId></ArticleIdList></Reference><Reference><Citation>Trauer J.M., Ragonnet R., Shipman D. Vynnycky and White, summerepi2 validation. 2022. https://github.com/monash-emu/summer-vynnycky-white-validation</Citation></Reference><Reference><Citation>Trauer J.M., Ragonnet R., Shipman D. A textbook of infectious disease modelling using the summer platform. 2023. https://github.com/monash-emu/summer-textbook</Citation></Reference><Reference><Citation>Van Elslande J., Oyaert M., Lorent N., Vande Weygaerde Y., Van Pottelbergh G., Godderis L., Van Ranst M., André E., Padalko E., Lagrou K., Vandendriessche S., Vermeersch P. Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection. Diagnostic Microbiology and Infectious Disease. 2022;103(1) doi: 10.1016/j.diagmicrobio.2022.115659. 2022/05/01/</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diagmicrobio.2022.115659</ArticleId><ArticleId IdType="pmc">PMC8837483</ArticleId><ArticleId IdType="pubmed">35278794</ArticleId></ArticleIdList></Reference><Reference><Citation>Vette K.M., Machalek D.A., Gidding H.F., Nicholson S., O'Sullivan M.V.N., Carlin J.B., Downes M., Armstrong L., Beard F.H., Dwyer D.E., Gibb R., Gosbell I.B., Hendry A.J., Higgins G., Hirani R., Hueston L., Irving D.O., Quinn H.E., Shilling H.…Macartney K. Seroprevalence of severe acute respiratory syndrome coronavirus 2-specific antibodies in Australia after the first epidemic wave in 2020: A national survey. Open Forum Infectious Diseases. 2022;9(3):ofac002. doi: 10.1093/ofid/ofac002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac002</ArticleId><ArticleId IdType="pmc">PMC8842318</ArticleId><ArticleId IdType="pubmed">35169588</ArticleId></ArticleIdList></Reference><Reference><Citation>Viana R., Moyo S., Amoako D.G., Tegally H., Scheepers C., Althaus C.L., Anyaneji U.J., Bester P.A., Boni M.F., Chand M., Choga W.T., Colquhoun R., Davids M., Deforche K., Doolabh D., du Plessis L., Engelbrecht S., Everatt J., Giandhari J.…de Oliveira T. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022;603(7902):679–686. doi: 10.1038/s41586-022-04411-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04411-y</ArticleId><ArticleId IdType="pmc">PMC8942855</ArticleId><ArticleId IdType="pubmed">35042229</ArticleId></ArticleIdList></Reference><Reference><Citation>Vynnycky E., White R. OUP oxford; 2010. An introduction to infectious disease modelling.</Citation></Reference><Reference><Citation>Wang H., Paulson K.R., Pease S.A., Watson S., Comfort H., Zheng P., Aravkin A.Y., Bisignano C., Barber R.M., Alam T., Fuller J.E., May E.A., Jones D.P., Frisch M.E., Abbafati C., Adolph C., Allorant A., Amlag J.O., Bang-Jensen B.…Murray C.J.L. Estimating excess mortality due to the COVID-19 pandemic: A systematic analysis of COVID-19-related mortality, 2020-21. The Lancet. 2022;399(10334):1513–1536. doi: 10.1016/S0140-6736(21)02796-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02796-3</ArticleId><ArticleId IdType="pmc">PMC8912932</ArticleId><ArticleId IdType="pubmed">35279232</ArticleId></ArticleIdList></Reference><Reference><Citation>Webster H.H., Nyberg T., Sinnathamby M.A., Aziz N.A., Ferguson N., Seghezzo G., Blomquist P.B., Bridgen J., Chand M., Groves N., Myers R., Hope R., Ashano E., Lopez-Bernal J., De Angelis D., Dabrera G., Presanis A.M., Thelwall S. Hospitalisation and mortality risk of SARS-COV-2 variant omicron sub-lineage BA.2 compared to BA.1 in England. Nature Communications. 2022;13(1):6053. doi: 10.1038/s41467-022-33740-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33740-9</ArticleId><ArticleId IdType="pmc">PMC9559149</ArticleId><ArticleId IdType="pubmed">36229438</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson N., Barnard L.T., Kvalsvig A., Verrall A., Baker M., Schwehm M. Modelling the potential health impact of the COVID-19 pandemic on a hypothetical European country. medRxiv. 2020 doi: 10.1101/2020.03.20.20039776. 2020.2003.2020.20039776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.03.20.20039776</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolter N., Jassat W., Walaza S., Welch R., Moultrie H., Groome M.J., Amoako D.G., Everatt J., Bhiman J.N., Scheepers C., Tebeila N., Chiwandire N., du Plessis M., Govender N., Ismail A., Glass A., Mlisana K., Stevens W., Treurnicht F.K.…Cohen C. Clinical severity of SARS-CoV-2 Omicron BA.4 and BA.5 lineages compared to BA.1 and Delta in South Africa. Nature Communications. 2022;13(1):5860. doi: 10.1038/s41467-022-33614-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-022-33614-0</ArticleId><ArticleId IdType="pmc">PMC9531215</ArticleId><ArticleId IdType="pubmed">36195617</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Guo Z., Yuan J., Cao G., Wang Y., Gao P., Liu J., Liu M. Duration of viable virus shedding and polymerase chain reaction positivity of the SARS-CoV-2 omicron variant in the upper respiratory tract: A systematic review and meta-analysis. International Journal of Infectious Diseases. 2023;129:228–235. doi: 10.1016/j.ijid.2023.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2023.02.011</ArticleId><ArticleId IdType="pmc">PMC9937726</ArticleId><ArticleId IdType="pubmed">36804640</ArticleId></ArticleIdList></Reference><Reference><Citation>Xin H., Li Y., Wu P., Li Z., Lau E.H.Y., Qin Y., Wang L., Cowling B.J., Tsang T.K., Li Z. Estimating the latent period of coronavirus disease 2019 (COVID-19) Clinical Infectious Diseases. 2022;74(9):1678–1681. doi: 10.1093/cid/ciab746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab746</ArticleId><ArticleId IdType="pubmed">34453527</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>